Business Description
Endonovo Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US29272H2013
Description
Endonovo Therapeutics Inc is an us-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Equity-to-Asset | -37.79 | |||||
| Debt-to-Equity | -0.29 | |||||
| Debt-to-EBITDA | 0.8 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | -153.39 | |||||
| Beneish M-Score | -34.33 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -66.8 | |||||
| 3-Year Book Growth Rate | 49.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.14 | |||||
| 9-Day RSI | 42.06 | |||||
| 14-Day RSI | 44.08 | |||||
| 6-1 Month Momentum % | -75.36 | |||||
| 12-1 Month Momentum % | -75.49 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Days Sales Outstanding | 5.18 | |||||
| Days Payable | 52514.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -135.1 | |||||
| Shareholder Yield % | 26.98 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 94.33 | |||||
| Operating Margin % | -2070.21 | |||||
| Net Margin % | 4912.06 | |||||
| FCF Margin % | 86.52 | |||||
| ROE % | Neg. Equity | |||||
| ROA % | 699.74 | |||||
| ROIC % | -13.43 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 0.48 | |||||
| EV-to-EBIT | 0.97 | |||||
| EV-to-EBITDA | 0.9 | |||||
| EV-to-Revenue | 56.34 | |||||
| EV-to-FCF | 65.11 | |||||
| Earnings Yield (Greenblatt) % | 103.09 | |||||
| FCF Yield % | 14.56 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ENDV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Endonovo Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.141 | ||
| EPS (TTM) ($) | 0.005 | ||
| Beta | -1.74 | ||
| Volatility % | 89.8 | ||
| 14-Day RSI | 44.08 | ||
| 14-Day ATR ($) | 0.000554 | ||
| 20-Day SMA ($) | 0.002757 | ||
| 12-1 Month Momentum % | -75.49 | ||
| 52-Week Range ($) | 0.001 - 0.02 | ||
| Shares Outstanding (Mil) | 349.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Endonovo Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Endonovo Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Endonovo Therapeutics Inc Frequently Asked Questions
What is Endonovo Therapeutics Inc(ENDV)'s stock price today?
The current price of ENDV is $0.00. The 52 week high of ENDV is $0.02 and 52 week low is $0.00.
When is next earnings date of Endonovo Therapeutics Inc(ENDV)?
The next earnings date of Endonovo Therapeutics Inc(ENDV) is .
Does Endonovo Therapeutics Inc(ENDV) pay dividends? If so, how much?
Endonovo Therapeutics Inc(ENDV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers